SCHEDULE: Ardsley Group Files Schedule 13G Amendment
Schedule 13G Amendment
Ardsley Advisory Partners LP and affiliated entities have filed an amendment to their Schedule 13G, reporting 0% beneficial ownership of Aspire Biopharma Holdings.
Summary
- This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership reporting for Aspire Biopharma Holdings.
- The reporting persons include Ardsley Advisory Partners LP, Ardsley Advisory Partners GP LLC, Ardsley Partners I GP LLC, Ardsley Partners Advanced Healthcare Fund, L.P., Ardsley Partners Fund II, L.P., and Philip J. Hempleman.
- As of the filing date, the aggregate beneficial ownership reported by these entities is 0 shares, representing 0% of the class of securities.
- The filing references the Issuer's Form S-1 dated December 3, 2025, which disclosed 138,446,102 outstanding shares of Common Stock.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it indicates a complete divestment or absence of beneficial ownership by a previously associated group, which could imply a lack of confidence or strategic shift away from the company.
Negatives
- The reporting entities collectively hold 0% of the outstanding common stock, indicating no significant beneficial ownership.
Future Outlook
No forward-looking statements or guidance were provided in this filing.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors who acquire beneficial ownership of more than 5% of a class of a company's securities. A filing reporting 0% ownership, especially as an amendment, suggests a divestment or a correction of previous filings, which can be a signal to the market.
Stakeholder Impact
- Shareholders: The absence of significant beneficial ownership by Ardsley and its affiliates may reduce market interest or indicate a lack of institutional support.
Key Dates
| Date | Description |
|---|---|
| 12/03/2025 | Date of Issuer's Form S-1 filing disclosing outstanding shares. |
| 12/31/2025 | Date of Event Which Requires Filing of this Statement. |
| 05/13/2026 | Date of signature for the Schedule 13G/A filing and Joint Filing Agreement. |
| 02/15/2006 | Date of Vaxgen, Inc. filing where Philip J. Hempleman's Power of Attorney was attached. |
Keywords
Schedule 13G, Beneficial Ownership, SEC Filing, Aspire Biopharma Holdings, Ardsley Advisory Partners, Amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.